Page 1,059«..1020..1,0581,0591,0601,061..1,0701,080..»

Changes in individual and contextual socio-economic level influence on reproductive behavior in Spanish women in the MCC-Spain study – BMC Blogs…

Posted: April 18, 2020 at 4:42 am

The most challenging result in our study is the emerging of socioeconomic inequalities in age at first delivery, number of pregnancies, number of alive newborns, and diagnosis of fertility problems in women born after 1950. Breastfeeding, suffering abortions or dead newborns, consumption of oral contraceptives or hormonal replacement therapy were associated with socioeconomic level in women born before 1950 but not in women born after that year.

Stratifying our analysis according to being born before or after 1950 was not arbitrary. It is noteworthy that women born in that year reached their sexual maturity around 1970, which would be considered some kind of social milestone for Spanish women. Spanish women incorporated to labor market after 1970, the labor activity rate in 1976 being 55.1% for women aged 2024 (i.e., born after 1950) and only 29.7% for women aged 2559 (i.e., born before 1950) [18]. Secondly, sexual behavior began to change in most western countries in the 60s, involving usage of contraceptives, family planning and women taking more control of their sexual / reproductive lives. The Spanish society, however, had their sexual habits ruled by the dictatorship that ended in the 70s, including for instance late initiation of sexual relationships, one partner only, or inclusion of adultery in the penal laws until 1976 [19]. Therefore, sexual freedom and generalized accessibility to contraceptives was reached by Spanish women from 1976 on, with some delay respect to women in other western countries. Thirdly, a deep economic crisis affecting Western countries (the so-called first oil shock) began in 1973. This eventually led to high unemployment rates and to deep falls in birth rates, which were more intense in Spain: the average number of children per women fell from 2.90 in 1970 to 2.22 in 1980 and 1.36 in 1990 (for comparison, figures in the UK were 2.43 in 1970 and 1.83 in 1990). In the same 20-year period, the birth rate fell in Spain from 19.5 in 1970 to 15.3 in 1980 and 10.3 newborns per 1000 inhabitants in 1990 (in the UK: 16.2 in 1970 and 13.9 in 1990) [20]. Fourthly, the public health service increased its coverage from 1970 to 1980, reaching universal coverage in 1988 [21]. Finally, the continued social trend toward reduced family size instead of that in the past, in rural areas above all, where children were needed and deemed to be suitable for farming or helping at home [22].

That social context could easily explain changes when the socioeconomic inequalities decreased in women born after 1950. For instance, hormonal contraceptives were marketed in Spain from 1964 on, but their indications initially included keeping the ovary in rest, controlling menstrual cycle, and treating dysmenorrhea and acne, while their contraceptive effect was considered as an undesirable side effect [23]. For years, they were more accessible for highly educated women living in urban areas [24]. When the public health service included contraception in its portfolio, women could access it without socioeconomic differences, leading to the results we have described for women born after 1950. Hormonal replacement therapy appeared much later than hormonal contraceptives, but its usage was amplified via private practicing doctors. This eventually resulted in higher consumption for women in higher socioeconomic levels; in 2001, when most women born after 1950 had not reached menopause, the Womens Health Initiative study found an association between hormonal replacement therapy and several cancers [25] and other chronic diseases [26], leading to a dramatic decrease in hormone replacement therapy in Spain [27].

The emergence of new socioeconomic disparities in age at first delivery and number of pregnancies in women born after 1950, however, is challenging. These inequalities appeared or were intensified in an era of universal coverage of the public health service, with free access to contraceptive methods and widely available information about them. In this regard, it is noteworthy that universal health coverage does not imply -by itself- equity in health assistance. For instance, the OECD have noticed that despite the fact that most OECD countries have achieved universal health coverage, people from the most socially disadvantaged groups tend to have worse access to health services. Possible reasons include lack of awareness of health services, poorer quality of care and co-payments for care [28,29,30]. In this regard, Spanish women aged 2544 (most of their fertile age) declared having unmet needs for health care in higher percentages if their income are in the lower quintile, although the gradient associated with income level was rather mild (5.84, 3.13, 4.15, 3.52 and 3.11% for Q1 to Q5 in 2001, [31]. Admittedly, these data on unmet needs in 2001 are too late for explaining our results, but National Health Surveys carried out before 2001 did not include any question on unmet needs. Apart from this explanation, we can only speculate on whether cultural issues associated with lower both socioeconomic and educational levels or differential access to work market could have prevented women in such levels to decrease their fertility as women in higher levels did. For instance, it could be possible that women in higher socioeconomic level incorporated earlier to the work market and, thus, delayed their decisions on having their first child. It is noteworthy, in this regard, that socioeconomic-level associated inequalities were mainly in drugs usage (hormonal contraceptives and hormone replacement therapy) in women born before 1950, which could be associated with inequities in accessing health care. The main inequalities in women belonging to later generations, however, seem to be associated with their own decisions (number and age of pregnancies), not with access to medical care. Along the same lines, a recent review carried out in 2019 showed how social determinants play an important role in the stage of breast cancer in diagnosis and survival [32].

Selection of population controls is a main strength of this study. Women aged 2085years were enrolled in 12 Spanish provinces after being selected from general practitioners roasters; they can provide a representative sample of the Spanish women, given the almost universal coverage of the national health system in Spain.

Some limitations of the study should also be noted. Firstly, reproductive variables were self-reported, which could lead to recall bias; however, as women were not aware of the hypotheses of this study, we would expect that recall bias -if exists- could be non-differential. Secondly, one of the SE indicators we have use -the Urban Vulnerability Index- is ecological by nature, which makes it possible the occurrence of ecological bias. In this regard, aggregate deprivation indexes have been found good proxies of individual income but less efficient to measure education or occupational category [33].

View post:
Changes in individual and contextual socio-economic level influence on reproductive behavior in Spanish women in the MCC-Spain study - BMC Blogs...

Posted in Hormone Replacement Therapy | Comments Off on Changes in individual and contextual socio-economic level influence on reproductive behavior in Spanish women in the MCC-Spain study – BMC Blogs…

Facts about menopause thatre not well known – Vanguard

Posted: April 18, 2020 at 4:42 am

The menopause has always been the bane of the average middle-aged woman. Hot flushes, weight gain, and diminished sex drive are all well-known symptoms of the dreaded menopause.

But research now confirms what women have long suspected; that it can affect the body and mind in many other ways. Tanith Carey takes a professional look at what you can do to tackle these surprising side-effects.

You start snoring: For years, youve been complaining that your partners snoring keeps you awake. Now the menopause is setting in, he could well be pointing the finger at you. Many women start snoringmore seriously once they hit the change of life which is 51 on average.

The onset of snorting is partly due to falling levels of female sex hormone oestrogen, whichas well as regulating the menstrual cyclealso plays a role in keeping the muscles and soft tissues around the wind-pipe strong.

When these become more lax, the tissues collapse and women cant breathe as easily when they sleep.

In the most serious cases, it can lead to sleep apnoea, where the airways become partially or totally obstructed for up to ten seconds at a time, forcing the brain to wake upeven though the sleeper may not be aware of it.

A study by the University of Toronto found that 47 per cent of post-menopausal women suffer with the conditioncompared to 21 per cent of younger women. Because the quality of sleep is impaired by the constant waking, side-effects can include tiredness, anxiety and forgetfulness.

How to fight back: Try buying a pillow designed to make you sleep on your backor with your head and throat in alignmentso your airways stay open as you sleep.

For women with serious cases of sleep apnoea, there are masks, called CPAP (Continuous Positive Airway Pressure), which blow air into the throat to keep breathing easier.

Youre lost for Words: Word on the tip of your tongue you just cant recall? Forgetting an oil friends name? It could be another symptom of the menopause.

In one study, 40 per cent of women aged 40-55 said they had trouble remembering things, even when their other thought processes remained as strong as ever.

Studies have shown that when oestrogen levels dip it is more difficult to build connections between brain cells, and to store and recall memories.

How to fight back: The good news is that, in most cases, its a phase which will have passed a year after your last period, according to neuro-psychiatrist Miriam Weber.

During this time, women have to face up to the fact that they need to do more to make sure information sinks in. She says: You shouldnt expect to be able to remember everything after hearing it just once.

Repeat it out loud, or say it back to the person to confirm itit will help you hold on to that information far longer. A study at Durham University also found that hormone replacement therapy (HRT) can rejuvenate the brain.

The research found it took years off a womans mental age because HRT helped the left and right sides of the brain to work better together.

You crave sugary treats: Theres a reason that cup-cakes and deserts look

more tempting than they used to studies have found, women develop a sweeter tooth as they go through the menopause. A study at Turkeys Ankara University found that 35 per cent of women said their palate was not as sensitive during the change of life, and that they craved stronger, sweeter tastes.

At the same time, as levels of the oestrogen and the other female sex hormone, progesterone drop, women become more prone to insulin resistancewhere the bodys cells dont respond as well to insulin, making sugar cravings soar.

How to fight back: To beat your sweet tooth, eat smaller, more regular meals containing lean proteins, which absorbed more slowly into the blood stream.

As our sensitively to sugar dropsand we may not taste the sweetnessits more important than ever to read food labels.

Dr. Marilyn Glenville, author of Healthy eating for menopause, says: You may decide to take less sugar in your teabut, it is the hidden added sugar in products that can be the major culprit.

It has been calculated that we could be taking in up to 46 teaspoons of added sugar in a day in the foods and drinks we consume. Swap sugar-free brands of tomato ketchup of spaghetti sauce.

You can replace sugar with xylitol, which is naturally found in fruits and berries and has a low glycaemic index (a measure of how fast blood sugar levels rise after eating).

vanguard

Related

See the original post here:
Facts about menopause thatre not well known - Vanguard

Posted in Hormone Replacement Therapy | Comments Off on Facts about menopause thatre not well known – Vanguard

Trans men who have been on testosterone can still be fertile – LGBTQ Nation

Posted: April 18, 2020 at 4:41 am

Freddy McConnell is a transgender man whose pregnancy was the subject of the film "Seahorse."Photo: Manuel Vazquez for "Seahorse"/Promotional image

A recent study from a fertility clinic in Massachusetts has found that transgender men who stop taking testosterone (T) had similar egg yields to cisgender women.

Boston IVF is a fertility clinic and research center, and they decided to look at years of data they had collected to see if T had a permanent effect on fertility, even after a transgender man stops taking it.

Related: How a transgender dad won the right to be the legal father of the child he carried

They found that about half of transgender men who wanted to become pregnant were undergoing hormone replacement therapy (HRT) before they tried to get pregnant. Those who were taking it stopped on average four months before undergoing ovarian stimulation cycles as part of an in-vitro fertilization process.

And they had similar egg yields to cisgender women who never took testosterone.

The landmark study involved data from 25 transgender men.

The numbers were very small, but it was very reassuring that even though these transgender men had taken testosterone, when they stopped it and were treated, they responded well and we had good outcomes, Boston IVF Medical Director Dr. Samuel Pang told NBC News.

The studys results flies in the face of the conventional wisdom that transgender men need to freeze eggs before starting T in order to one day have children.

Emmett Hardiman said that he knew he was transgender since he was young and he started HRT when he turned 18. He thought that he was definitely going to be infertile.

I had to make a choice, he said.

But his period started again several years later when he stopped T due to a lack of insurance. He had eggs harvested and his wife carried two children who came from those eggs. (Fertility experts recommend trans men go off hormones to collect and freeze eggs, although one 16-year-old trans boy reportedly was able to have eggs harvested without going off hormones.)

Dr. Pang said that even though its possible for trans men to go off HRT to have a child, that can still be asking too much.

The thought of stopping testosterone or going through hormone treatments if very daunting for them, so they frequently will not pursue it because of that, he said.

Just having to go off testosterone in order to do IVF was not a great option, but it was, to me, better than the alternative, said Hardiman.

The study looked at transgender men who started HRT as adults. Dr. Johanna Olson-Kennedy, medical director of the Center for Transyouth Health and Development at Childrens Hospital Los Angeles, said that it would probably be different for trans men who took puberty blockers and then moved directly on to T since their reproductive organs never matured.

We dont know because no one has ever done it, she said. It stands to reason that somebody would, because your hypothalamus doesnt change.

Read more:
Trans men who have been on testosterone can still be fertile - LGBTQ Nation

Posted in Testosterone Replacement Therapy | Comments Off on Trans men who have been on testosterone can still be fertile – LGBTQ Nation

Global Testosterone Replacement Therapy Market 2020 Regional Analysis, Growth Prospects, Size, Outlook and Forecast 2025 – Galus Australis

Posted: April 18, 2020 at 4:41 am

Magnifier Research published a Global Testosterone Replacement Therapy Market Report 2020, Forecast to 2025 which provides a comprehensive study on the market, comprising a nitty-gritty and fair-minded evaluation of this market. The markets segmentation and the significant market verticals are considered while evaluating its industrial chain, production chain, manufacturing capacity, sales volume, and revenue. The research is a meticulous study of the global Testosterone Replacement Therapy market which portrays each and every detail of the market. It provides an overview of market segmentation such as type, application, and region. It also lists the drivers, limitations, and opportunities available in the market.

Some well-known companies identified to operate in the global market are: AbbVie, Endo International, Eli lilly, Pfizer, Actavis (Allergan), Bayer, Novartis, Teva, Mylan, Upsher-Smith, Ferring Pharmaceuticals

Factors that are contributing to the growth of a specific type of product category and factors that are motivating the status of the market highlighted in the report. The report covers the details on market acquisitions, mergers, and significant trends that are influencing the growth of the global Testosterone Replacement Therapy market in the coming years from 2020 to 2025. During the report compilation, analysts have used established and beneficial tools and techniques such as SWOT analysis and Porters Five Forces analysis to carry out the research study. The geographical scope of the products is also taken into consideration.

DOWNLOAD FREE SAMPLE REPORT: https://www.magnifierresearch.com/report-detail/40135/request-sample

On the basis of product type, this report displays the shipments, revenue (Million USD), price, and market share and growth rate of each type: Gels, Injections, Patches, Other

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, shipments, revenue (Million USD), price, and market share and growth rate for each application: Hospitals, Clinics, Others

An All-Inclusive Framework of The Geographical Terrain:

The global Testosterone Replacement Therapy market report covers market shares for global, North America (United States, Canada and Mexico), Europe (Germany, France, UK, Russia and Italy), Asia-Pacific (China, Japan, Korea, India and Southeast Asia), South America (Brazil, Argentina, Colombia etc.), Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa). The analysis of this report has been used to examine various segments that are relied upon to witness the quickest development based on the estimated forecast frame. Moreover, data concerning growth opportunities for the market across every detailed region is included in the report. The anticipated growth rate expected to be recorded by each region over the estimated years has been given within the research report.

ACCESS FULL REPORT: https://www.magnifierresearch.com/report/global-testosterone-replacement-therapy-market-report-2020-forecast-40135.html

Opportunities in The Global Testosterone Replacement Therapy Market Report:-

Customization of the Report:This report can be customized to meet the clients requirements. Please connect with our sales team (sales@magnifierresearch.com), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

About Us

Magnifier Research is a leading market intelligence company that sells reports of top publishers in the technology industry. Our extensive research reports cover detailed market assessments that include major technological improvements in the industry. Magnifier Research also specializes in analyzing hi-tech systems and current processing systems in its expertise. We have a team of experts that compile precise research reports and actively advise top companies to improve their existing processes. Our experts have extensive experience in the topics that they cover. Magnifier Research provides you the full spectrum of services related to market research, and corroborate with the clients to increase the revenue stream, and address process gaps.

Contact UsMark StoneHead of Business DevelopmentPhone: +1-201-465-4211Email: sales@magnifierresearch.comWeb: http://www.magnifierresearch.com

Continued here:
Global Testosterone Replacement Therapy Market 2020 Regional Analysis, Growth Prospects, Size, Outlook and Forecast 2025 - Galus Australis

Posted in Testosterone Replacement Therapy | Comments Off on Global Testosterone Replacement Therapy Market 2020 Regional Analysis, Growth Prospects, Size, Outlook and Forecast 2025 – Galus Australis

Unified website for biotechnology regulation recently launched – Daily Herald

Posted: April 16, 2020 at 9:46 pm

WASHINGTON, D.C. In recognition of National Biotechnology Month, the U.S. Department of Agriculture (USDA), the Food and Drug Administration (FDA) and the Environmental Protection Agency (EPA) recently launched a unified website for biotechnology regulation.

The website streamlines information about the three regulatory agencies charged with overseeing agriculture biotechnology products and is part President Donald J. Trumps Executive Order on Modernizing the Regulatory Framework for Agricultural Biotechnology Products.

Agricultural biotechnology has been and will continue to be an essential tool in helping Americas farmers and ranchers feed, fuel and clothe the world, said U.S. Secretary of Agriculture Sonny Perdue.

From producers to consumers, all Americans deserve a government that delivers science-based, common-sense regulations that foster innovation, conserve resources, and protect public healthespecially when it comes to the food supply, said Perdue.

The launch of this unified biotechnology regulation website is proof of President Trumps commitment to provide the American people with sensible regulations in a clear and transparent manner.

EPA is pleased to be working with our partners at USDA, FDA, and across the federal government to implement President Trumps Executive Order and launch this new, coordinated website, said EPA Administrator Wheeler.

This new website will help provide regulatory certainty and clarity to our nations farmers and producers by bringing together information on the full suite of actions the Trump Administration is taking to safely reduce unnecessary regulations and breakdown barriers for these biotechnology products in the marketplace, Wheeler said.

This is a time of unprecedented scientific innovation. Agricultural biotechnology promises to bring dynamic new products to the marketplace, said FDA Commissioner Stephen Hahn, M.D.

At the FDA, we are committed to fostering flexible, risk-based approaches in this field while upholding our mission of protecting and promoting both human and animal health and animal well-being, Hahn said.

For example, by reducing their susceptibility to diseases like novel influenzas and resistance to zoonotic or foreign animal diseases. Our approach balances our internationally respected, science-based review standards, Hahn said, with our ongoing risk-based regulatory approaches to ensure the safety of our food supply.

Background

The Unified Website for Biotechnology Regulation describes the federal review process for certain biotechnology products and allows users to submit questions to the three agencies.

The goals of this website are to provide enhanced customer service to innovators and developers, while ensuring Americans continue to enjoy the safest and most affordable food supply in the world and can learn more about the safe use of biotechnology innovations.

For more information, visit https://usbiotechnologyregulation.mrp.usda.gov/biotechnologygov/home/.

Go here to see the original:
Unified website for biotechnology regulation recently launched - Daily Herald

Posted in Biotechnology | Comments Off on Unified website for biotechnology regulation recently launched – Daily Herald

Viewpoint: How consumer fear and misguided regulation limit the progress of crop biotechnology – Genetic Literacy Project

Posted: April 16, 2020 at 9:46 pm

Theres a profound disconnect between what the latest gene-editing methods can do to increase yields and enhance crop disease and stress resistance and the trickle of such improved crops actually getting out into farmers fields.

The first generation of genetically modified (GM) crops has been remarkably successful. The whole world eats food containing ingredients derived from GM crops and feeds them to its myriad agricultural animals and pets. Despite many dire predictions of long-term negative health effects, a quarter century has passed and none have materialized.1 This remarkably clean track record should have assuaged public fears and assured the rapid development and adoption of GM crops of all kinds.

But it hasnt.

Decades after four major commodity biotech crops corn, soybeans, cotton and canola were introduced and rapidly soared to near market saturation in the countries that permitted their cultivation, the number of new GM crops being released to farmers remains tiny.

[Editors note: This article is part one of a four-part series on the progress of agricultural biotechnology. Read part two and part three.]

Yet the need for higher yielding, disease-resistant and stress-tolerant crops grows with each passing year. The pressures of population growth and climate warming are already outpacing the speed with which conventional breeding practices are expanding the global food supply.2 Land and water availability are rapidly becoming limiting, hence the focus is sharply on the intensification of agriculture.3 But the breeding methods that fueled the spectacular advances in agricultural productivity over the 20th century are near exhaustion.

Over the same period, knowledge of plant physiology and genetics has grown at an explosive pace, as has the technology for identifying and modifying genes of agronomic interest. We know vastly more about what genes do and how plant genomes change both naturally and under human intervention than we did even when the first GM crops were introduced in 1996.4

The recent invention and rapid development of gene- or genome-editing technology (aka SSN or sequence-specific nuclease technology) has facilitated a quantum leap in the ease and precision of genetic intervention, positioning researchers to accelerate the increase in crop yields and to make crop plants more resilient to the biotic and abiotic stresses exacerbated by climate warming.5

Yet just a few of the crops that need to be improved are being improved using the latest techniques and of those, only a few reach farmers each year. To understand this deep disconnect between what can be done to improve crops using modern molecular techniques and what is being done requires a look at the tangle of issues around GM technology at the interface between science, business and society.

In this four-part series, I first examine the factors that led to the disconnect between what can be done and what is being done. I then review both the successes and failures of the first generation of GM crops modified using recombinant DNA (rDNA) technology. I next introduce the new gene-editing technologies and what they promise. And finally, I take a look at the regulatory, political and business decisions that actually determine what gets out of research laboratories and into farmers fields. The entire essay is available as a single publication from the author. Please email [emailprotected].

Part 1: The origins of the disconnect between the science and the farmer

Public resistance to innovation is not unusual, but hardly universal. People line up for the newest Apple iPhone, but have to be persuaded to try a GM apple that doesnt turn brown. Resistance generally subsides as a technology is widely adopted and proves harmless. GM technology in medicine, for example, is now broadly accepted, be it human insulin or any of the many new protein-based therapeutics. But the controversies around GM crops have persisted, and indeed intensified through the deliberate vilification efforts of both individuals and organizations.6,7

According to polls, the public remains largely ignorant of what GM organisms (GMOs) are and of how modern molecular methods fit into the long history of crop improvement.8 Because fear-based disinformation strategies are so effective, what has grown instead is the widespread conviction that GMOs are bad, meaning variously that they are harmful to health, unnatural, or produced by big biotech companies that unfairly exploit farmers.7,9

Part of the problem is that public awareness of genetic modification in agriculture is recent, arguably dating back only to the late 1980s when controversies erupted over field testing of the so-called ice-minus bacterium modified to eliminate a protein that promotes ice formation on the leaves of strawberries.10 Yet in a strictly scientific context, genetic modification denotes the entire spectrum of human interventions in the genetics of other organisms over more than 10 millenia.11

For crop plants, these encompass domestication, breeding, mutation breeding and, most recently, genetic improvement by molecular techniques. All involve genetic changes, aka mutations. Domestication and conventional plant breeding rely on organisms inherent genetic variation.

Direct genetic manipulation of crop plants using chemical and radiation mutagenesis (mutation breeding) dates back to the 1930s.12 But even now, few people other than plant breeders are aware that crops have long been improved through deliberate efforts to induce new mutations using both chemicals and irradiation. So today, it is the general understanding that genetically modified organisms (GMOs) are only those that have been modified by molecular methods. That is, most people think genetic modification is quite new.

And then theres what the regulators built

As if this were not sufficiently problematic, the way in which the regulatory environment evolved reinforced suspicions about GM safety. Early efforts to regulate the commercial introduction of GM crops emphasized the need to regulate new crop traits rather than the particular method by which they were introduced. But thats not what happened.

Starting from the beginning of the regulatory activities in the late 1980s, the U.S. agencies that oversee GM organisms have regulated only organisms modified by molecular methods and theyve regulated all of them, without regard to either nature of the organism or the trait that was added.13 This has been true of the US Department of Agriculture (USDA) and the Environmental Protection Agency (EPA), although the Food and Drug Administration has generally followed its practice of post-market oversight. None of the agencies subjected new crop varieties produced by the older methods of chemical and radiation mutagenesis to regulatory oversight.

Complying with the regulatory requirements proved not only time consuming and prohibitively expensive to developers,14 but also reinforced the altogether unfounded popular conviction that molecular methodology is dangerous. Both negative popular views of GM foods and the high regulatory costs associated with their introduction have shaped the present availability of GMOs in agriculture. Indeed, it is virtually impossible to understand the contemporary paucity of GM crop varieties without considering both regulatory and acceptance issues.

The recent development of gene-editing methods has led to a new round of public and bureaucratic controversy worldwide over what should be classified as a GMO and subject to regulatory oversight. Because gene-editing techniques15 introduce the same kinds of mutations as the older mutagenesis methods, crops modified by gene editing can be indistinguishable at the molecular level from those improved by mutation breeding.

Mutation breeding has been in safe use for a century, hence there is no scientifically defensible rationale for imposing regulations on crops with the same kinds of genetic changes produced by the new, far more precise methods. This is being recognized in some countries by decreasing the regulatory burden on certain types of crop modifications produced by gene-editing techniques.

However, in 2018 the European Court of Justice ruled that gene-edited crops should undergo the same level of regulatory scrutiny as crops modified by older molecular methods.16 As they have over the past 4 decades, the outcome of such regulatory decisions will profoundly influence the kinds of genetic improvements that will be undertaken and actually become available to farmers and consumers.

Thus both public opinion and regulatory practices have made major contributions to the disconnect between the modern science of crop improvement and the farmer.

1EC (2010). A decade of EUfunded GMO research (20012010). European Commission https://ec.europa.eu/research/biosociety/pdf/a_decade_of_eu-funded_gmo_research.pdf; NASEM (2016). Genetically Engineered Crops: Experiences and Prospects. National Academies of Sciences, Engineering, and Medicine 978-0-309-43735-6 http://www.nap.edu/catalog/23395/genetically-engineered-crops-experiences-and-prospects

2Ray DK et al. (2013). Yield trends are insufficient to double global crop production by 2050. PloS One 8:e66428.

3Tilman D et al. (2011). Global food demand and the sustainable intensification of agriculture. Proc Natl Acad Sci USA 108:20260-4.

4Richroch AE (2013). Assessment of GE food safety using -omics techniques and long-term animal feeding studies. New Biotechnol 30:351-54; Fedoroff NV (2013). Plant transposons and genome dynamics in evolution. (Wiley-Blackwell, Oxford, UK), p.212; Anderson JE et al. (2016). Genomic variation and DNA repair associated with soybean transgenesis: a comparison to cultivars and mutagenized plants. BMC Biotechnol 16:41.

5Podevin N et al. (2013). Site-directed nucleases: a paradigm shift in predictable, knowledge-based plant breeding. Trends Biotechnol 31:375-83; Zhang D et al. (2016). Targeted gene manipulation in plants using the CRISPR/Cas technology. J Genet Genomics 43:251-62; Zhang Y et al. (2019). The emerging and uncultivated potential of CRISPR technology in plant science. Nature Plants 5:778-94.

6Apel A (2010). The costly benefits of opposing agricultural biotechnology. New Biotechnol 27:635-40.

7Ryan CD et al. (2019). Monetizing disinformation in the attention economy: The case of genetically modified organisms (GMOs). European Management J 38:7-18.

8Funk C et al. (2015). Public and scientists views on science and society. Pew Research Center http://www.pewinternet.org/2015/01/29/public-and-scientists-views-on-science-and-society/

9Funk C and Kennedy B (2016). Public opinion about genetically modified foods and trust in scientists connected with these foods. Pew Research Center http://www.pewinternet.org/2016/12/01/public-opinion-about-genetically-modified-foods-and-trust-in-scientists-connected-with-these-foods/

10Palca J (1986). Ice-minus bacteria: Further snag and further delay. Nature 320:2.

11Fedoroff NV (2015). Food in a future of 10 billion. Agricult Food Security 4:11.

12Ahloowalia B et al. (2004). Global impact of mutation-derived varieties. Euphytica 135:187-204.

13Fedoroff NV (2013). Will common sense prevail? Trends Genet 29:188-9; Wolt JD et al. (2016). The regulatory status of genomeedited crops. Plant Biotechnol J 14:510-8; Van Eenennaam A and Fedoroff N. How the federal government can get biotech regulation right. Des Moines Register, 1 March 2018

14McDougall P (2011). The cost and time involved in the discovery, development and authorisation of a new plant biotechnology derived trait. Crop Life International https://croplife.org/plant-biotechnology/regulatory-2/cost-of-bringing-a-biotech-crop-to-market/

15Kleter GA et al. (2019). Gene-edited crops: towards a harmonized safety assessment. Trends Biotechnol 37:443-7.

16Kupferschmidt K (2018). EU verdict on CRISPR crops dismays scientists. Science 361:435.

Nina V. Fedoroff is an Emeritus Evan Pugh Professor atPenn State University

Read the original here:
Viewpoint: How consumer fear and misguided regulation limit the progress of crop biotechnology - Genetic Literacy Project

Posted in Biotechnology | Comments Off on Viewpoint: How consumer fear and misguided regulation limit the progress of crop biotechnology – Genetic Literacy Project

Biotechnology Industry: Does Iovance Biotherapeutics Inc (IOVA) Stock Beat its Rivals? – InvestorsObserver

Posted: April 16, 2020 at 9:46 pm

The 72 rating InvestorsObserver gives to Iovance Biotherapeutics Inc (IOVA) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 84 percent of stocks in the Biotechnology industry, IOVAs 72 overall rating means the stock scores better than 72 percent of all stocks.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 72 means the stock is more attractive than 72 percent of stocks.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

Iovance Biotherapeutics Inc (IOVA) stock has risen 13.99% while the S&P 500 is unchanged 0% as of 9:50 AM on Tuesday, Apr 14. IOVA is higher by $4.23 from the previous closing price of $30.23 on volume of 285,317 shares. Over the past year the S&P 500 is down -4.95% while IOVA is higher by 209.06%. IOVA lost -$1.59 per share the over the last 12 months.

To screen for more stocks like IOVA click here.

Read the rest here:
Biotechnology Industry: Does Iovance Biotherapeutics Inc (IOVA) Stock Beat its Rivals? - InvestorsObserver

Posted in Biotechnology | Comments Off on Biotechnology Industry: Does Iovance Biotherapeutics Inc (IOVA) Stock Beat its Rivals? – InvestorsObserver

Researchers Move Closer to Industrial Production of Heparin in Cell Culture – Genetic Engineering & Biotechnology News

Posted: April 16, 2020 at 9:46 pm

Scientists at the University of California-San Diego say they have moved one step closer to the ability to make heparin in cultured cells. Heparin is a potent anti-coagulant and the most prescribed drug in hospitals, yet cell-culture-based production of heparin is currently not possible, according to the researchers who published their study, ZNF263 is a transcriptional regulator of heparin and heparan sulfate biosynthesis in PNAS.

In particular, the researchers found a critical gene in heparin biosynthesis: ZNF263 (zinc-finger protein 263). The team believes this gene regulator is a key discovery on the way to industrial heparin production. The idea would be to control this regulator in industrial cell lines using genetic engineering, paving the way for safe industrial production of heparin in well-controlled cell culture.

Heparin is the most widely prescribed biopharmaceutical in production globally. Its potent anticoagulant activity and safety makes it the drug of choice for preventing deep vein thrombosis and pulmonary embolism. In 2008, adulterated material was introduced into the heparin supply chain, resulting in several hundred deaths and demonstrating the need for alternate sources of heparin. Heparin is a fractionated form of heparan sulfate derived from animal sources, predominantly from connective tissue mast cells in pig mucosa. While the enzymes involved in heparin biosynthesis are identical to those for heparan sulfate, the factors regulating these enzymes are not understood, write the investigators.

Examination of the promoter regions of all genes involved in heparin/heparan sulfate assembly uncovered a transcription factor-binding motif for ZNF263, a C2H2 zinc finger protein. CRISPR-mediated targeting and siRNA knockdown of ZNF263 in mammalian cell lines and human primary cells led to dramatically increased expression levels of HS3ST1, a key enzyme involved in imparting anticoagulant activity to heparin, and HS3ST3A1, another glucosaminyl 3-O-sulfotransferase expressed in cells. Enhanced 3-O-sulfation increased binding to antithrombin, which enhanced Factor Xa inhibition, and binding of neuropilin-1. Analysis of transcriptomics data showed distinctively low expression of ZNF263 in mast cells compared with other (nonheparin-producing) immune cells. These findings demonstrate a novel regulatory factor in heparan sulfate modification that could further advance the possibility of bioengineering anticoagulant heparin in cultured cells.

The UC San Diego scientists reasoned that heparin synthesis must be under the control of transcription factors, whose tissue-specific occurrence might give mast cells the unique ability to produce heparin. Since regulators for heparin were not known, a research team led by UC San Diego professors Jeffrey Esko, PhD, and Nathan Lewis, PhD, used bioinformatic software to scan the genes encoding enzymes involved in heparin production and specifically look for sequence elements that could represent binding sites for transcription factors. The existence of such a binding site could indicate that the respective gene is regulated by a corresponding gene regulator protein, i.e. a transcription factor.

One DNA sequence that stood out the most is preferred by a transcription factor called ZNF263 (zinc-finger protein 263), explains Lewis, who holds appointments in the UC San Diego School of Medicines Department of Pediatrics and in the UC San Diego Jacobs School of Engineerings Department of Bioengineering.

Using CRISPR/Cas9, the researchers mutated ZNF263 in a human cell line that normally does not produce heparin. They found that the heparan sulfate that this cell line would normally produce was now chemically altered and showed a reactivity that was closer to heparin. Experiments further showed that ZNF263 represses key genes involved in heparin production. Analysis of gene expression data from human white blood cells showed suppression of ZNF263 in mast cells (which produce heparin in vivo) and basophils, which are related to mast cells. The researchers report that ZNF263 appears to be an active repressor of heparin biosynthesis throughout most cell types, and mast cells are enabled to produce heparin because ZNF263 is suppressed in these cells.

This finding could have important relevance in biotechnology. Cell lines used in industry (such as CHO cells that normally are unable to produce heparin) could be genetically modified to inactivate ZNF263 which could enable them to produce heparin, like mast cells do.

Philipp Spahn, PhD, a project scientist in the Lewis lab, described further directions the team is pursuing: Our bioinformatic analysis revealed several additional potential gene regulators which can also contribute to heparin production and are now exciting objects of further study.

See the original post:
Researchers Move Closer to Industrial Production of Heparin in Cell Culture - Genetic Engineering & Biotechnology News

Posted in Biotechnology | Comments Off on Researchers Move Closer to Industrial Production of Heparin in Cell Culture – Genetic Engineering & Biotechnology News

Reasons Why Long-term Faith on Vir Biotechnology, Inc. (VIR) Could Pay Off Investors – The InvestChronicle

Posted: April 16, 2020 at 9:46 pm

Vir Biotechnology, Inc. (VIR) is priced at $29.50 after the most recent trading session. At the very opening of the session, the stock price was $29.75 and reached a high price of $29.9, prior to closing the session it reached the value of $29.90. The stock touched a low price of $29.15.

Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stocks existing status and the future performance. Presently, Vir Biotechnology, Inc. shares are logging -60.67% during the 52-week period from high price, and 153.21% higher than the lowest price point for the same timeframe. The stocks price range for the 52-week period managed to maintain the performance between $11.65 and $75.00.

The companys shares, operating in the sector of healthcare managed to top a trading volume set approximately around 1.32 million for the day, which was evidently higher, when compared to the average daily volumes of the shares.

When it comes to the year-to-date metrics, the Vir Biotechnology, Inc. (VIR) recorded performance in the market was 134.59%, having the revenues showcasing 123.15% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 3.20B, as it employees total of 229 workers.

During the last month, 3 analysts gave the Vir Biotechnology, Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 1 analysts were recommending to HOLD this stock, 1 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.

According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 23.08, with a change in the price was noted +16.65. In a similar fashion, Vir Biotechnology, Inc. posted a movement of +129.57% for the period of last 100 days, recording 687,913 in trading volumes.

Total Debt to Equity Ratio (D/E) can also provide valuable insight into the companys financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders equity. The total Debt to Equity ratio for VIR is recording 0.00 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.00.

Raw Stochastic average of Vir Biotechnology, Inc. in the period of last 50 days is set at 22.76%. The result represents improvement in oppose to Raw Stochastic average for the period of the last 20 days, recording 8.85%. In the last 20 days, the companys Stochastic %K was 9.35% and its Stochastic %D was recorded 9.02%.

Bearing in mind the latest performance of Vir Biotechnology, Inc., several moving trends are noted. Year-to-date Price performance of the companys stock appears to be pessimistic, given the fact the metric is recording 134.59%. The shares increased approximately by 1.57% in the 7-day charts and went up by -19.62% in the period of the last 30 days. Common stock shares were driven by 123.15% during last recorded quarter.

See the original post:
Reasons Why Long-term Faith on Vir Biotechnology, Inc. (VIR) Could Pay Off Investors - The InvestChronicle

Posted in Biotechnology | Comments Off on Reasons Why Long-term Faith on Vir Biotechnology, Inc. (VIR) Could Pay Off Investors – The InvestChronicle

Is Inovio Pharmaceuticals Inc (INO) Stock Near the Top of the Biotechnology Industry? – InvestorsObserver

Posted: April 16, 2020 at 9:46 pm

Inovio Pharmaceuticals Inc (INO) is near the top in its industry group according to InvestorsObserver. INO gets an overall rating of 72. That means it scores higher than 72 percent of stocks. Inovio Pharmaceuticals Inc gets a 83 rank in the Biotechnology industry. Biotechnology is number 6 out of 148 industries.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

Inovio Pharmaceuticals Inc (INO) stock has risen 8.82% while the S&P 500 is lower by -0.22% as of 10:32 AM on Thursday, Apr 16. INO is up $0.63 from the previous closing price of $7.14 on volume of 5,210,923 shares. Over the past year the S&P 500 is down -4.25% while INO is up 108.87%. INO lost -$1.21 per share the over the last 12 months.

To screen for more stocks like INO click here.

Read more here:
Is Inovio Pharmaceuticals Inc (INO) Stock Near the Top of the Biotechnology Industry? - InvestorsObserver

Posted in Biotechnology | Comments Off on Is Inovio Pharmaceuticals Inc (INO) Stock Near the Top of the Biotechnology Industry? – InvestorsObserver

Page 1,059«..1020..1,0581,0591,0601,061..1,0701,080..»